X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will leverage PostEra's AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen's drug discovery expertise, to advance up to 5 small molecule programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2023
Details:
ASAP will use PostEra's end-to-end AI-first approach to accelerate the discovery process, generating molecules with optimised properties, designing rapid synthesis, and optimally prioritising experiments.
Lead Product(s): Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $68.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 18, 2022
Details:
PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform.
Lead Product(s): Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Breyer Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
